Pacira BioSciences to sell iovera° unit to Zimmer Biomet for up to $140M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
June 30, 2026 7:30 AM EDT-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments --
-- Two companies will collaborate on advancing the spasticity program --
-- Supports 5x30 strategy and advances Paciras transition into an innovative biopharmaceutical company --
BRISBANE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced... More
